Prescribing ADHD Meds by Telehealth Does Not Alter Risk for Substance Use Disorder Overall
By Elana Gotkine HealthDay Reporter
TUESDAY, June 17, 2025 -- Receipt of a stimulant prescription for attention-deficit/hyperactivity disorder (ADHD) via telehealth is not associated with an increased risk for substance use disorder (SUD), according to a study published online June 11 in The American Journal of Psychiatry.
Vinod Rao, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues conducted a retrospective cohort study using electronic health record data from March 1, 2020, to Aug. 25, 2023, to examine whether receiving an initial prescription for ADHD from a provider who the patient has never seen in person is associated with an increased risk for stimulant use disorder (stimUD) or other SUDs. A total of 7,944 patients were included in the sample.
The researchers found that a purely telehealth-based relationship versus any in-person relationship did not affect the risk for SUD or stimUD after adjustment for covariates. Compared with an in-person appointment, a telehealth visit at the time of the initial stimulant prescription did not alter the risk for subsequent SUD, but was associated with an increased risk for stimUD (adjusted odds ratio, 6.18).
"While we think the findings should be replicated, the vast majority of the data show no increase in substance use disorder developing when patients exclusively use telehealth," coauthor Timothy Wilens, M.D., from Massachusetts General Hospital, said in a statement. "Our study supports the use of telehealth for ADHD stimulant therapy in clinical settings."
Two authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...
Current Medical Use of Rx Stimulants for ADHD Up in Teens From 2005 to 2023
TUESDAY, Aug. 5, 2025 -- Among U.S. adolescents, current medical use of prescription stimulants for attention-deficit/hyperactivity disorder (ADHD) increased between 2005 and...
Insomnia Plays a Role in Quality of Life for Patients With ADHD
MONDAY, July 21, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) symptoms are associated with lower quality of life (QoL) in adults, and this association is only partially...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.